BiondVax Pharmaceuticals (NASDAQ: BVXV) Complementing Core Focus with CDMO Offering

May 23, 2023 10:51:48

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company aims to complement its core focus, nanosized antibody (“NanoAb”) pipeline development, with a comprehensive CDMO (contract development and manufacturing organization) offering. “With significant experience including developing its previous flu vaccine candidate, BiondVax intends to share its expertise, human resources and facilities with pharma companies to develop and manufacture their drug candidates for preclinical use as well as clinical testing,” a recent article reads. “BiondVax’s CDMO services cover aseptic fill and finish, upstream and downstream process development, as well as analytical model development, among others. In addition, the company also offers comprehensive CDMO services geared toward supporting pilot, clinical and process development stages, alternative protein food tech, pharmaceutical and biotech companies. The offering is intended to generate additional revenues for BiondVax and is made possible by the company’s growing assets ranging from GMP-ready production clean rooms to a 250mL Ambr(R) Fermentor and 2L and 5L fermentors for upstream process optimization. The company also offers Water for Injection (‘WFI’), 30L and 300L fermentors for upstream GMP production in addition to analytic tools, media and buffer preparation.”

To view the full article, visit https://ibn.fm/rCSZk

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork